Humulin M3 (Mixture 3) (Insulin Human)

Humulin M3 is indicated for the management of blood glucose levels in patients with diabetes mellitus.

• Provides basal and prandial insulin coverage for type 1 diabetes.
• Used as part of a comprehensive insulin regimen for type 2 diabetes when oral agents are insufficient.
• May be employed in patients requiring a fixed ratio of short‑acting to intermediate‑acting insulin.
• Can be used in hospital settings for rapid glycemic control during surgery or acute illness.
• Suitable for patients who prefer fewer daily injections compared with separate insulin preparations.

• Humulin M3 contains human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, thereby lowering endogenous glucose production. The mixture’s short‑acting component acts within minutes, while the intermediate‑acting portion provides a prolonged basal effect.

Adverse reactions to Humulin M3 may vary in frequency and severity.

Common

• Hypoglycemia (low blood glucose) manifesting as sweating, tremor, palpitations, anxiety, or confusion.
• Local injection‑site reactions such as redness, swelling, itching, or mild bruising.
• Lipodystrophy, including lipohypertrophy or lipoatrophy at the site of repeated injections.
• Gradual weight gain often observed with improved glycemic control and increased caloric intake.

Serious

• Severe hypoglycemia that may result in loss of consciousness, seizures, or the need for emergency assistance.
• Allergic reactions ranging from urticaria and angioedema to anaphylactic shock.
• Fluid retention or peripheral edema, particularly in patients with underlying cardiac or renal impairment.
• Hypersensitivity responses such as eosinophilia, serum‑sickness–like syndrome, or vasculitis.

When prescribing or using Humulin M3, clinicians and patients should consider several precautionary measures to minimize risks.

• Assess renal and hepatic function, as impaired clearance can prolong insulin action.
• Adjust doses during periods of reduced food intake, illness, or increased physical activity.
• Monitor blood glucose closely when initiating therapy or changing the insulin ratio.
• Use caution in pregnant or breastfeeding individuals; benefits should outweigh potential risks.
• Review patient history for previous insulin allergy or severe hypoglycemia episodes.
• Consider cardiovascular status, as rapid glucose shifts may affect heart disease patients.
• Store the product according to label instructions, protecting it from extreme temperatures.

Humulin M3 may interact with other medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid

• Concurrent use of other rapid‑acting insulin analogues without dose adjustment.
• Beta‑blockers that can mask hypoglycemia symptoms.
• MAO‑A inhibitors, which may potentiate insulin’s hypoglycemic effect.

Use with caution

• Oral antidiabetic agents such as sulfonylureas or meglitinides, requiring close glucose monitoring.
• Corticosteroids, which can raise blood glucose and necessitate higher insulin doses.
• Thiazide diuretics, which may affect electrolyte balance and glucose control.
• Alcohol, especially in excess, as it can cause unpredictable glucose fluctuations.